{
  "ticker": "ILA",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973333",
  "id": "02973333",
  "pages": 39,
  "price_sensitive": false,
  "date": "20250728",
  "time": "1322",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250728/pdf/06m6qmcqtqvjrk.pdf",
  "summary": "### **Summary of ASX Announcement (Investor Roadshow & Presentation)**  \n\n- **Announcement Type**: Investor Presentation & Roadshow  \n- **Material Points**:  \n  - **Galidesivir (Marburg/Ebola program)**: Potential FDA approval via Animal Rule pathway; could secure a **Priority Review Voucher (PRV)** (recent PRVs valued at **US$103\u2013158M**).  \n  - **ISLA-101 (Dengue)**: Positive Phase 2a/b results:  \n    - **Preventative cohort**: Viral load reduced **10\u201315x**, symptom duration shortened by **2 days** vs. placebo.  \n    - **Treatment cohort**: Trend toward efficacy (one outlier with low drug concentration).  \n  - **Upcoming Catalysts**:  \n    - Galidesivir acquisition completion (**August 2025**).  \n    - FDA meetings for both programs (**Q4 2025**).  \n    - Planned Marburg animal study (**Q4 2025**).  \n  - **Financials**: **$7.25M cash** (as of 30 June 2025).  \n\n**Omitted**: Roadshow logistics, historical data, non-material pipeline details.",
  "usage": {
    "prompt_tokens": 7606,
    "completion_tokens": 256,
    "total_tokens": 7862,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T05:11:17.310524"
}